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neither significantly limits tubulointerstitial fibrosis. The long-Hypertension and renal injury in experimental polycystic kid-
term studies give clear support to the importance of bloodney disease.
pressure control, per se, but only partial support to the impor-Background. Hypertension accelerates renal failure in auto-
tance of the particular agent used. As in clinical studies, angio-somal dominant polycystic kidney disease (ADPKD), and evi-
tensin-converting enzyme inhibition may be less beneficial indence suggests a role for the renin-angiotensin system (RAS)
ADPKD than in renal diseases characterized by predominantin the functional and structural changes. To explore the hypoth-
glomerular injury.esis that RAS adaptations contribute to disease progression,
we examined RAS activity and the long-term consequences of
antihypertensive drugs, which suppress (enalapril) or stimulate
(hydralazine) the RAS, in experimental polycystic kidney disease.
One of the most common hereditary diseases, autoso-Methods. Studies were conducted in male heterozygous cys-
mal dominant polycystic kidney disease (ADPKD), rep-tic Han:SPRD rats (Cy/1) and in unaffected littermates (con-
trols). In protocol 1, either angiotensin II (Ang II), enalaprilat, resents approximately 10% of the cases of end-stage
or saline vehicle was acutely infused into cystic and control renal disease in the United States. Clinical and experi-
rats, which were aged 10 to 12 weeks. The mean arterial pres- mental studies have provided a detailed record of thesure (MAP), glomerular filtration rate (GFR), and renal plasma
clinical, physiological, and molecular manifestations offlow (RPF) were measured at baseline and after an infusion of
ADPKD [1–4], and two of the genes that are associatedtest substances. In protocol 2, cystic rats received chronic ther-
apy with either enalapril, hydralazine, or no therapy for 10 to with ADPKD have been isolated [5, 6]; however, the
12 weeks of age and then underwent renal function and RAS mechanisms that result in cyst formation and renal fail-
studies. In protocol 3, similar cohorts were followed for 40 weeks ure are complex. Complicating this issue are the longto assess the effects of therapy on blood pressure, proteinuria,
and variable clinical course to renal failure and, untilserum creatinine, RAS parameters, and renal morphology.
recently, the lack of a comparable experimental modelResults. In protocol 1, cystic rats had massive kidneys, slightly
elevated blood pressure, and profound renal vasoconstriction of ADPKD.
and reduced GFR. Ang II induced similar changes in MAP An important factor that accelerates renal failure in
and renal function in control and cystic rats. Enalaprilat in-
ADPKD is hypertension [3, 7–10]. Hypertension occursduced little effect on MAP but more striking increases in GFR
prior to a loss of renal function in 50 to 75% of patientsand RPF in cystic rats. In protocol 2, at 10 weeks of age, enalapril
was superior in preserving renal function, but neither drug with ADPKD. In addition, renal size has been correlated
limited the expansion of the tubulointerstitium. In protocol 3, with hypertension [11], suggesting a relationship be-
at 40 weeks of age, both drugs ameliorated the increase in tween hypertension and cyst growth. Angiographic anal-
serum creatinine, although only enalapril reduced proteinuria
ysis of polycystic kidneys reveals a marked distortion ofand kidney size.
the renal vascular tree and cystic compression of sur-Conclusions. In polycystic rats, acute RAS suppression mark-
edly ameliorates renal dysfunction. However, although chronic rounding tissue, suggesting that vascular attenuation and
enalapril and hydralazine protect against the loss of renal func- parenchymal ischemia may be contributing to the gener-
tion, only enalapril limits renal growth and proteinuria, and ation of hypertension and progression of renal failure in
this disorder [12]. Findings of low renal plasma flow
(RPF), high renal vascular resistance (RVR), and eleva-Key words: PKD, angiotensin, hydralazine, interstitial fibrosis, progres-
sive renal disease. tion of filtration fraction [7, 13, 14], as well as severe
sclerosis of the preglomerular vessels even early in theReceived for publication December 15, 1998
course of the disease [15], are further evidence for rela-and in revised form July 23, 1999
Accepted for publication July 27, 1999 tive intrarenal vasoconstriction in ADPKD.
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article is suggestive of an important influence of the inulin clearance and RPF from PAH clearance were
determined using standard formulas. The mean arterialrenin-angiotensin system (RAS). That the RAS may be
involved in the pathogenesis of hypertension and renal pressure (MAP) was also recorded during each collection
period, and RVR was calculated from measurementsinjury in ADPKD is further suggested by observations
of: higher values for plasma renin activity (PRA) in hy- obtained. Following these baseline measurements, rats
received either normal saline, Ang II (0.2 mg/kg/min),pertensive ADPKD patients [16]; attenuated hemody-
namic responses to exogenous angiotensin II (Ang II) or enalaprilat (2 mg bolus, then a continuous infusion of
2 mg/hr). Following a 30-minute period of equilibration,infusion [17], suggesting down-regulation of Ang II re-
ceptors; and normalization of RVR and filtration fraction functional measurements were repeated during the ex-
perimental period. After the experiments, blood waswith angiotensin-converting enzyme inhibition (ACEI)
[14, 18]. Additionally, the failure of RAS suppression in taken for the measurement of the plasma renin concen-
tration (PRC).hypertensive subjects with ADPKD, despite evidence of
increased circulating volume, suggests that maladaptive
Protocol 2: Chronic treatment studies (10 weeks)stimulation of the RAS may be a central feature in these
derangements [9, 10, 16]. To examine the chronic functional and morphologic
effects of manipulations of the RAS, additional groupsIn the current study, we examined the hypothesis that
important adaptations of the RAS occur in experimental of cystic rats were given either no therapy, enalapril (50
mg/liter in the drinking water), or hydralazine (160 mg/ADPKD and that these effects result in a primary and
maladaptive defect in vascular regulation that ultimately liter), beginning at weaning (age of three weeks). Control
rats were given tap water. At ages 10 to 12 weeks, six tocontributes to disease progression. We studied several
aspects of RAS biochemistry and physiology, as well as nine rats per group underwent surgical preparation and
baseline functional studies as described in protocol 1.the long-term consequences of antihypertensive therapy,
which suppresses (enalapril) or stimulates (hydralazine) After the hemodynamic measurements, kidneys were
prepared for morphologic studies as described later inthe RAS, in the Han:SPRD model of experimental poly-
cystic kidney disease. this article.
Protocol 3: Chronic treatment studies (40 weeks)
METHODS
Rats were prepared and treated with either hydrala-
The autosomal dominant polycystic kidney zine or enalapril as described in protocol 2. These groups
disease model of rats (N 5 6 to 10/group) were followed up to 40 weeks
of age, with serial measurements of tail cuff blood pres-These studies were conducted in male Han:SPRD rats,
which were raised in a breeding colony propagated from sure and 24-hour measurements of urinary protein excre-
tion. At 40 weeks, rats were sacrificed, with blood andbreeding pairs kindly provided by Dr. Benjamin Cowley
(University of Kansas Medical Center, Kansas City, KS, tissue obtained for measurements of plasma renin con-
centration (PRC), serum creatinine (SCr), and plasmaUSA). Heterozygous cystic rats (Cy/1) and unaffected
littermate control rats (1/1) were studied. All rats were and renal Ang II levels, and kidneys were prepared for
morphologic studies as described later in this article.fed standard rat chow (Rodent Laboratory Chow 5001;
Purina Mills, Richmond, IN, USA) ad libitum and had
Renal function studiesfree access to water. These studies were approved by
the Portland Veterans Affairs Institutional Animal Care Rats were anesthetized with Inactin (100 mg/kg intra-
peritoneally) and placed on a thermoregulated table.and Use Subcommittee.
The left femoral artery was cannulated, and a baseline
Protocol 1: Acute treatment studies sample of blood was collected for determination of Hct
and inulin and PAH blanks. This arterial catheter wasTo examine the systemic hemodynamic and renal func-
tional roles of the RAS in polycystic kidney disease, used for subsequent blood sampling and for the estima-
tion of MAP via an electronic transducer connected toacute intravenous infusions of either Ang II, enalaprilat,
or normal saline vehicle (time controls) were adminis- a direct writing recorder. After tracheostomy, bilateral
internal jugular catheters were inserted for infusions oftered to cystic and control rats (age 10 to 12 weeks, N 5
7 to 9 per group). Following surgical preparation for rat serum, and 10% inulin with 1.0% PAH in saline (1.2
ml/hr). To adjust for reduced renal clearances, cystic ratsfunctional studies and after a one-hour period of equili-
bration, all rats underwent two timed (20 min) urine were given 6% inulin with 0.6% PAH in saline. A femo-
ral venous catheter was used for the delivery of studycollections for the determination of flow rates, inulin,
and paraaminohippuric acid (PAH). Blood was obtained drugs, and the left ureter was catheterized for urine col-
lections. To maintain euvolemia, rat serum was infusedsimultaneously for measurement of hematocrit (Hct),
inulin, and PAH. Glomerular filtration rate (GFR) from at 0.1 ml/min for a total equal to 1% of the body weight,
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Table 1. Baseline systemic and renal parameters at 10 weeks of agefollowed by a reduction in infusion rate to 0.42 ml/hr,
to maintain a constant Hct. Control rats Cystic rats
(N 5 23) (N 5 24) P value
Biochemical studies BW g 33568 33567 .0.05
LKW g 1.5560.05 4.5360.13 ,0.001For the calculation of GFR, inulin concentrations in
LKW/100 g BW 0.46 60.01 1.3760.04 ,0.001
plasma and urine were determined by the macro-anthrone MAP mm Hg 12162 13362 ,0.001
GFR ml/min 1.5660.05 0.7660.03 ,0.001method. RPF was determined by PAH clearance, with
RPF ml/min 5.8960.24 2.6160.15 ,0.001PAH concentrations in plasma and urine determined FF 0.2760.01 0.3060.01 ,0.05
by colorimetric methodology. PRC was measured by RVR mm Hg/(ml/min) 12.560.6 33.862.2 ,0.001
incubating 100 ml of rat plasma with 100 ml rat anephric Abbreviations are: BW, body weight; LKW, left kidney weight; MAP, mean
arterial pressure; GFR, glomerular filtration rate; RPF, renal plasma flow rate;plasma and 400 ml of 0.2 m maleate buffer, pH 6.0, at
FF, filtration fraction; RVR, renal vascular resistance.
378 for one hour. Appropriate dilutions of rat plasma
samples were made using Tris buffer. The generation of
Ang I was then determined by radioimmunoassay using
commercially available reagents (New England Nuclear, distributed were analyzed by nonparametric methods.
Boston, MA, USA). Ang II was measured using the Statistical significance was defined as P , 0.05.
methods of Fox et al [19]. Blood was collected by cardiac
puncture into a prechilled syringe, with 1 ml being rapidly
RESULTSplaced into 9 ml cold methanol. Kidneys were rapidly
Protocol 1homogenized in 10 ml of cold methanol. Samples were
extracted using a phenyl-bonded SPE column (Bond- The results of protocol 1, in which acute hemodynamic
Elut; Varian, Harbor City, CA, USA). Ang II levels were responses to RAS stimulation or suppression were deter-
quantitated by radioimmunoassay, using rabbit anti-Ang mined in rats aged 10 weeks, are depicted in Tables 1
II antisera (Peninsula, Belmont, CA, USA), monoiodi- and 2 and Figure 1. Because baseline values in the various
nated 125I-labeled Ang II (Amersham, Arlington Heights, control and cystic groups were comparable, they were
IL, USA), and Ang II standards (Sigma, St. Louis, MO, pooled for analysis (Table 1). Body weights were compa-
USA). Renal Ang II levels were expressed as fmol Ang II rable, whereas values for both the left kidney weight and
per mg kidney (wet) weight and also as fmol/mg protein. the kidney/body weight ratio were markedly increased
Renal protein content was measured using a bicinchoni- (approximately threefold) in the cystic rats as compared
nic acid (BCA) protein assay kit (Pierce, Rockford, IL, with noncystic controls. Although the Han:SPRD rats
USA), using bovine serum albumin (BSA) as the stan- do not develop severe hypertension, they were slightly
dard. Urinary protein was measured by precipitation hypertensive as compared with the unaffected control
with 3% sulfosalicylic acid. rats. By 10 weeks of age, renal functional impairment
was apparent, with markedly reduced values for GFR
Morphometric studies and RPF. The marked vasoconstriction was associated
Renal morphometry was assessed quantitatively using with significant elevations in filtration fraction and in
the point counting method. Kidneys were prepared by RVR (Table 1).
10% formalin fixation, and slides were stained using he- The effects of acute infusion of Ang II, enalaprilat,
matoxylin and eosin staining. Subcapsular cortical fields and saline vehicle are depicted in Table 2 and Figure 1.
were assessed using a rigid protocol for random position- Saline vehicle had no significant effect on any parameter
ing. Cystic kidneys were assessed at low power (3100) in either group. In noncystic control rats, Ang II induced
to avoid sampling variations produced by massive cystic a significant increase in MAP. GFR was relatively un-
dilation. Control rats were assessed at 3400. Cysts, which changed, whereas RPF was markedly reduced (246 6
were distinguished from tubules by their flattened epi- 7% as compared with baseline; Fig. 1). These changes
thelial surfaces, were avoided and not counted. Results were associated with marked increases in filtration frac-
are expressed as a percentage of the total area. tion and in RVR (1140 6 27%). In cystic rats receiving
Ang II, the systemic pressor response was similar to
Statistics that in noncystic controls. GFR was not affected. The
Values are reported as means 6 sem. Statistical analy- decrement in RPF and increment in RVR were greater
sis was performed by paired t-test (for studies before than in the control rats, whereas a similar percentage of
and after an intervention) or by paired t-test or analysis reductions in RPF (246 6 6%) and increments in filtra-
of variance followed by computation of modified t-values tion fraction and RVR (1134 6 27%) was seen.
according to the method of Bonferroni (for multiple Enalaprilat induced modest, but not significant, reduc-
tions in MAP in both control and cystic groups. In controlgroups), as appropriate. Values that were not normally
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Table 2. Effects of angiotensin II and enalaprilat on systemic and renal hemodynamic function
GFR RPF
MAP RVR PRC
Group Period mm Hg FF mm Hg/(ml/min) ng Ang I/ml/hrml/min
C 1 NS (N 5 7) 1 12062 1.4060.09 5.0860.37 0.2860.01 14.361.3 77 618
2 11863 1.4460.09 5.3160.37 0.2760.01 14.361.3
D 2262 10.0460.05 10.2360.33 20.0160.01 20.761.1
Cystic 1 NS (N 5 7) 1 13463 0.7060.06 2.3160.26 0.3160.02 39.164.3 9 62c
2 12965 0.7560.06 2.4160.27 0.3260.01 36.964.6
D 2663 10.0560.04 10.0960.11 10.0160.01 22.262.5
C 1 Ang II (N 5 8) 1 11964 1.5060.06 5.7160.22 0.2760.02 12.460.8 10 61b
2 13964a 1.3760.14 3.0360.27a 0.4560.01a 28.762.2a
D 12064a,b 20.1360.13 22.6860.42a,b 10.1860.01a,b 116.262.8a,b
Cystic 1 Ang II (N 5 8) 1 13462 0.8560.06 2.8760.30 0.3160.02 30.263.9 4 61b,c
2 15065a 0.7160.05 1.4860.17a,b 0.5160.05a,b 67.467.7a,b
D 11764a,b 20.1460.06 21.3960.24a,b,c 10.2060.04a,b 137.267.4a,b,c
C 1 Enal (N 5 7) 1 12463 1.7760.08 6.7760.43 0.2760.02 11.160.7 403 6111b
2 11964 1.8860.14 7.9860.24a 0.2460.01a 9.160.4
D 2564 10.1160.10 11.2160.48a 20.0360.01a 22.060.5
Cystic 1 Enal (N 5 9) 1 13263 0.7360.05 2.6060.20 0.2960.02 33.062.8 45 615b,c
2 12964 1.0960.09 3.7760.40a 0.3060.01 23.962.7
D 2462 10.3660.07a,b 11.1760.32a 10.0160.01 29.161.8a
Period 1 5 baseline. Period 2 5 experimental.
Abbreviations are: C, control rats; NS, normal saline; Ang II, angiotensin II; Enal, enalapril; D, difference between Periods 1 and 2; PRC, plasma renin concentration;
other abbreviations as in Table 1.
a P , 0.05 vs. baseline (Period 1)
b P , 0.05 vs. NS group or change in NS group
c P , 0.05 vs. change in corresponding controls
Differences between control and cystic rats in baseline periods in each group were similar to those in Table 1, and are not shown.
rats, GFR was unaffected, whereas RPF increased. The and renal vasoconstriction with elevated RVR. Blood
pressure was equivalently and significantly reduced byfiltration fraction fell slightly, and RVR was numerically,
but not statistically, reduced slightly as well. Of note, enalapril and hydralazine. Both antihypertensive regi-
mens had beneficial effects on renal hemodynamic func-renal hemodynamic responses to enalaprilat were much
more striking in the cystic rats, particularly when ex- tion numerically, but enalapril afforded superior im-
provement. As compared with untreated cystic rats, onlypressed as a percentage change from baseline. Prominent
increases in both GFR (152 6 11%) and RPF (146 6 the rats receiving enalapril had statistically higher values
for GFR and RPF. Hydralazine-treated rats had lower14%) were noted (Fig. 1). Filtration fraction was un-
changed, whereas RVR fell significantly (228 6 5%). values for filtration fraction, and both groups had signifi-
cant reductions in RVR.Thus, although acute hemodynamic responses to exoge-
nous Ang II were not different in the cystic rats, the Although still enlarged as compared with normal ani-
mals, kidneys in both treated groups were smaller thaneffects of acute blockade of Ang II formation with enala-
prilat were markedly enhanced. those in the untreated cystic rats, presumably reflecting
a diminished cyst burden. However, despite the preser-Of note, the aforementioned hemodynamic responses
occurred in the absence of systemic RAS activation. In vation of GFR with enalapril, morphologic studies did
not find significant preservation of renal structure in ei-fact, values for PRC were consistently reduced in the
cystic rats, even with the stimuli of anesthesia and surgery ther group. Morphometric analysis revealed, as ex-
pected, prominent increases in the percentage of the(Table 2). In control rats, PRC values were appropriately
reduced by Ang II infusion and were increased by enala- kidney taken up by tubular lumens and the interstitium in
the untreated cystic rats. Neither antihypertensive drugprilat. Directionally similar responses occurred in the
cystic rats, but values under all conditions were signifi- significantly limited the tubulointerstitial expansion.
cantly lower than those noted in control animals.
Protocol 3
Protocol 2 Results of long-term (up to age 40 weeks) studies with
enalapril and hydralazine are summarized in Table 4. AtThe results of studies of short-term treatment with
hydralazine and enalapril are summarized in Table 3. the final systolic blood pressure determination, untreated
cystic rats were clearly hypertensive, and blood pressuresBody weights were similar in all groups. As compared
with the noncystic controls, cystic rats again exhibited were equivalently reduced with the two antihypertensive
drugs. Time-averaged values for blood pressure, span-slightly higher blood pressures (though not significantly)
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both enalapril and hydralazine increased PRC values.
Blood Ang II levels tended to follow the patterns sug-
gested by the PRC values and the known effects of these
drugs. Blood Ang II levels were low in the cystic rats
and in cystic rats treated with enalapril, although values
in hydralazine rats were higher and closer to those in
control rats. When expressed per gram of wet kidney
weight, renal Ang II levels were comparable in control
and untreated cystic rats and were reduced with enalapril
but not hydralazine. Given the markedly different kidney
weights, we also examined renal Ang II factored per mg
renal protein. When so factored, renal Ang II levels were
slightly reduced in the cystic rats, clearly reduced in
the enalapril-treated rats, and markedly increased in the
hydralazine-treated cystic rats.
Morphologic patterns tended to follow those seen at
10 weeks: marked expansion of the tubulointerstitium
in the cystic rats, without significant modification by anti-
hypertensive therapy. Although differences in the per-
centage of morphologic structures did not differ, the
lower kidney weights in the enalapril-treated rats most
likely reflected diminution in total cyst burden.
DISCUSSION
These studies were conducted in the Han:SPRD model
of ADPKD, which has proven highly useful in reflecting
the major pathophysiological features of the human dis-
ease [20–22]. In this model, homozygous affected animals
develop rapid renal failure and do not survive past the
first month. The heterozygotes grow normally and sur-
Fig. 1. Effects of saline vehicle (h), angiotensin II (Ang II; j), and vive for approximately 8 to 12 months, while developingenalapril ( ) in control and cystic rats, expressed as a percentage
the major renal manifestations of the disease: progressivechange in glomerular filtration rate (GFR; A) and renal plasma flow
rate (RPF; B) from baseline values. *P , 0.05 vs. baseline; †P , 0.05 renal enlargement caused by cyst formation, tubulointer-
vs. change in control rats. stitial fibrosis, and impairment of GFR [20].
When studied at 10 weeks of age, the male Han:SPRD
rats were already manifesting the major features of the
disease. Although hypertension was less severe than thatning the entire treatment period, revealed the same pat-
seen in some other models of progressive renal disease,tern. Cystic rats developed moderate and significant pro-
it was generally present, confirming findings in previousteinuria, which was attenuated by enalapril but not
studies in this model [22, 23] and in humans with thehydralazine. Body weights were slightly reduced in the
disease [7–10]. Blood pressure values in the unaffectedenalapril-treated rats but were comparable in the other
littermate controls were within the normal range andgroups. Renal enlargement was again apparent in the
were similar to those in the parent Sprague-Dawleyuntreated rats. Values for left kidney weight were mark-
strain, confirming that the blood pressure elevation wasedly lower in the enalapril group, although the difference
associated with the polycystic disease. Clearance studieswas less apparent when factored for body weight. Gross
confirmed profound renal vasoconstriction, with reducedheart weights and heart/body weight ratios were signifi-
values for GFR and RPF, and elevated values for filtra-cantly increased in the untreated cystic rats and were
tion fraction (FF) and RVR; these findings are similarreduced only with enalapril. Renal function, as assessed
to those noted in young adults with relatively earlyby serum creatinine, was markedly impaired in the cystic
ADPKD [8, 13, 14, 24, 25].rats. Of note, both hydralazine and enalapril treatment
The mechanisms of this intense renal vasoconstrictionameliorated renal dysfunction so that serum creatinine
remain incompletely defined. Renal parenchymal ische-elevations were markedly attenuated.
mia, resulting from compression induced by massive cys-Values for PRC were markedly reduced in the cystic
rats, as compared with noncystic controls. As expected, tic enlargement, has been postulated to play a role, per-
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Table 4. Effects of enalapril and hydralazine on the kidney at 40 weeks of age
Control Cystic Cystic/enal Cystic/hydral
(N 5 6) (N 5 9) (N 5 10) (N 5 9)
Final SBP mm Hg 11364 158 69a 11664b 10863b
Average SBP mm Hg 12163 130 66a 11062a,b 10762a,b
UprotV mg/day 461 54612a 2462a,b 78618a,b
BW g 48066 483 614 444 610b 45866
LKW g 1.6860.03 3.65 60.43a 2.1460.31b 3.5360.24a,c
LKW/100 g BW 0.35 60.01 0.77 60.10a 0.6460.03 0.77 60.05a
HW g 1.4760.03 1.73 60.07a 1.3860.05b 1.6960.05
HW/100 g BW 0.31 60.01 0.36 60.02a 0.3160.01b 0.3760.01a,c
Serum Cr mg/dl 0.6960.4 2.01 60.51a 1.0360.05b 0.9860.04b
PRC ng Ang I/ml/hr 2263 4 60.2a 64613a,b 43617a,b
Blood Ang II fmol/ml 1963 6 62a 1063 16 62b
LK Ang II fmol/g 124611 79 628 28 65a,b 109628c
LK Ang II fmol/mg prot 1.4260.17 0.97 60.13a 0.6660.17a 3.0860.97a,b,c
% Tubules (cells) 71.964.7 22.2 64.3a 21.562.1a 26.262.3a
% Tubules (lumen) 7.560.7 30.264.4a 28.362.3a 22.061.7a
% Tubules (total) 79.364.5 52.4 61.3a 49.862.0a 48.262.9a
% Glomeruli 7.261.4 4.8 60.5a 4.560.4a 4.060.4a
% Vessels 0.360.1 1.3 60.3a 0.760.1 1.4 60.3a
% Interstitium 8.761.8 41.561.3a 45.162.0a 46.563.2a
Abbreviations are: SBP, systolic blood pressure; UprotV, 24-hour urinary protein excretion; HW, heart weight; Cr, creatinine; PRC, plasma renin concentration;
other abbreviations as in Tables 1–3.
a P , 0.05 vs. controls
b P , 0.05 vs. cystic rats
c P , 0.05 vs. cystic/enal rats
Table 3. Effects of enalapril and hydralazine on the kidney at 10 weeks of age
Control rats Cystic rats Cystic/enal Cystic/hydral
(N 5 8) (N 5 6) (N 5 9) (N 5 9)
BW g 32568 330 66 313 610 303610
MAP mm Hg 12262 132 66 107 62a,b 11163a,b
GFR ml/min 1.8260.05 0.78 60.08a 1.2860.08a,b 0.9260.08a,c
RPF ml/min 6.8360.31 2.55 60.25a 4.4060.37a,b 3.8960.46a
FF 0.2760.01 0.31 60.01 0.28 60.01 0.2560.02b
RVR mm Hg/(ml/min) 10.960.5 33.0 62.9a 15.861.6b 19.262.2a,b
LKW g 1.4660.05 5.02 60.33a 3.6360.14a,b 4.0460.18a,b
LKW/100 g BW 0.45 60.01 1.52 60.09a 1.1760.05a,b 1.3360.04a
% Tubules (cells) 72.065.0 20.6 62.4a 26.962.1a 26.061.8a
% Tubules (lumen) 11.962.8 26.9 63.7a 25.161.4a 29.061.5a
% Tubules (total) 83.962.3 47.5 63.9a 52.062.4a 55.162.5a
% Glomeruli 7.161.1 3.1 60.3a 3.960.2a 3.360.5a
% Vessels 0.160.1 0.8 60.4 0.4 60.1 0.560.1
% Interstitium 8.862.3 48.663.9a 43.862.5a 41.062.7a
Abbreviations are: enal, enalapril; hydral, hydralazine; other abbreviations as in Table 1.
a P , 0.05 vs. controls
b P , 0.05 vs. cystic rats
c P , 0.05 vs. cystic/enal rats
haps by stimulating the RAS (discussed later in this creases RPF [29]. Studies in animal models have invoked
a role for epidermal growth factor [4, 30], which in addi-article). Other hormonal mediators that might contribute
have received relatively little study. It has been reported tion to its growth promoting effects, is known to cause
renal vasoconstriction in normal animals [31]. Little isin ADPKD patients that plasma endothelin (ET) levels
are elevated [24], that ET is present in human cyst fluid known of the activity of the nitric oxide system in this
disease, although recent preliminary reports noted im-[26], and that there is a linear association between ET
and blood pressure in hypertensive patients [27]. The paired endothelium-dependent vasodilation in ADPKD
patients, which was not improved with administration ofintrarenal ET system is also activated in animal models.
In the cpk mouse model, ET and ET receptor mRNAs l-arginine (abstract; Wang et al, J Am Soc Nephrol,
8:383A, 1997), and failure of l-arginine to slow the pro-increase in parallel with cyst growth [28]. ET levels are
also elevated in the Han:SPRD model, and combined gression of cystic disease in Han:SPRD rats (abstract;
Yoshida et al, J Am Soc Nephrol 9:385A, 1998).ETA/ETB receptor antagonism reduces MAP and in-
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The RAS is being increasingly recognized to promote ide, and therefore, contributions of these mechanisms
cannot be excluded as explanations for the effects ofrenal injury via a number of different mechanisms. The
most well known are the typical hemodynamic effects enalaprilat.
Despite the clear evidence for a functional role ofinduced by Ang II (hypertension, decreases in renal
blood flow more than in GFR, increases in efferent arte- Ang II, we were unable to biochemically document any
activation of the RAS. In fact, PRCs were consistentlyriolar resistance, filtration fraction and glomerular capil-
lary pressure, and reduction in the ultrafiltration coeffi- reduced in cystic rats, even when stimulated by anesthesia
and surgery, or in the presence of enalaprilat. Studiescient). More recently, it has been recognized that Ang II
also promotes renal injury by effects on cellular growth, in the 40-week rats, which were done under very brief
anesthesia, confirmed continuing reduction in PRC andmesangial matrix formation, elaboration of cytokines,
and stimulation of interstitial fibrosis [32]. In most mod- in circulating Ang II levels as well. We were also unable
to document activation of the intrarenal RAS using mea-els of glomerular disease, the amelioration of abnormal
intrarenal hemodynamic derangements is associated surements of Ang II. Previous studies in kidneys from
ADPKD patients have noted hyperplasia of the juxta-with reduction of proteinuria and glomerular sclerosis
[33, 34]. More recently, it has been noted that an inter- glomerular renin apparatus, with no clear increase in
renin-containing cells in that location, but redistributionruption of the RAS with ACEI or Ang II AT1 receptor
antagonists can slow the progression of diseases, which and expansion of renin immunoreactivity into blood ves-
sels and the tubulointerstitium [42, 43], as well as inare more tubulointerstitial in nature, such as chronic
puromycin nephrosis [35], cyclosporine nephrotoxicity the cystic epithelium and the cyst fluid [15]. In contrast,
studies in the Han:SPRD model have generally noted[36], and chronic allograft rejection [37]. In some of these
cases, such as cyclosporine nephrotoxicity [38], there is suppression of both systemic and intrarenal renin forma-
tion [21, 22]. In accordance with the renin findings, wean apparent dissociation between functional protection
(preservation of GFR) and structural protection (limita- found that renal Ang II levels were similar or possibly
reduced in cystic rats as compared with normal controls.tion of fibrosis).
This dissociation may prove to be the case in ADPKD. These observations notwithstanding, a full understand-
ing of the intrarenal RAS in this disease remains to beOur data in this study confirm previous observations that
the RAS plays a prominent role in mediating the renal developed. Despite the massively enlarged kidneys, the
reduction in functioning renal parenchymal mass in thehemodynamic changes in this model, at least in the ear-
lier phases. Acute administration of the ACEI enalapri- cystic rats may have contributed to the reduced levels
seen at the whole kidney level. Our studies did not ad-lat had a trivial effect on blood pressure, but a profound
effect on renal hemodynamics, increasing GFR and RPF dress the localization of intrarenal Ang II or other renal
RAS components. Whether the RAS (its componentsby some 50%. Such an exuberant response to RAS inhi-
bition is unusual; even in models in which chronic ACEI or receptors) is activated in the cystic kidney or perhaps
in specific (for example, vascular) compartments thereinis protective, such as experimental diabetes or renal abla-
tion, the acute hemodynamic responses are quite modest awaits further testing. Because Ang II is only one media-
tor in a panoply of opposing vasoconstrictors and vasodi-[39, 40]. The clearly enhanced renal response to ACEI
is quite consistent with the hypothesis that the intrarenal lators, it remains possible that even low levels of RAS
activity are important in the absence of appropriate vaso-RAS is activated in this model, exerting a strong and
tonic influence on renal vascular tone. In analogy, the dilatory compensation. In any event, the hemodynamic
studies clearly indicate an important role for this systemactivation of the intrarenal RAS has similarly been in-
voked to explain observations of enhanced renal vascular in mediating renal hemodynamic function.
We next explored the importance of the RAS inresponsiveness to Ang II receptor antagonism in some
patients with diabetes, despite the absence of systemic chronic studies, comparing the hemodynamic and struc-
tural sequelae of antihypertensive regimens, which sup-RAS activation [41]. Intrarenal RAS activation has pre-
viously also been invoked to explain attenuated Ang II press (enalapril) and stimulate (hydralazine) the RAS.
In glomerular diseases, drugs that block the RAS andresponsiveness in patients with ADPKD [17]. However,
such altered responsiveness is not universally found clini- ameliorate glomerular hypertension are superior to those
agents that do not block that system [44–46]. Our studiescally (abstract; Iversen et al, J Am Soc Nephrol 8:374A,
1997), and we found equivalent responsiveness to Ang with enalapril are similar to those noted in two previous
studies of ACEI [22, 23], in which rats were studied atII in both cystic and control rats. Future studies using
direct renal intra-arterial infusions to eliminate con- slightly older ages (3 to 5 months). In the studies of
Ogborn, Sareen, and Pinette, amelioration of renal growthfounding effects of changes in systemic vascular hemody-
namics may prove useful in further defining this issue. and serum creatinine were noted with cilazapril, even
though the degree of blood pressure reduction was im-Alternatively, the administration of an ACEI is known
to influence the levels of both bradykinin and nitric ox- perfect [23]. In the studies of Keith et al, both enalapril
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and the AT1 receptor antagonist losartan were effective case, the failure to restrict sodium intake may have atten-
in preserving renal function (as assessed by serum creati- uated the beneficial effects of ACEI.
nine) and structure (measured as cyst burden) [22]. As- However, in other parameters, the two drugs were
suming that cyst burden correlates with kidney weight, more equivalent. Both attenuated progressive renal in-
our findings are in agreement. However, those studies sufficiency, as reflected by serum creatinine values. Al-
did not specifically evaluate the parameter of tubuloin- though serum creatinine is not a sensitive reflection of
terstitial expansion. GFR in the rat, there were clear differences between
Hydralazine (with or without diuretics) has generally the treated and untreated rats and clearly no difference
been ineffective, although in some models, it appears to among rats receiving antihypertensive drugs. Similarly,
be protective early in the course of the disease [44]. morphologic injury, as reflected by expansion of the in-
Using equi-antihypertensive doses, we found that hydral- terstitial area, and attendant fibrosis appeared to be
azine was less effective than enalapril at attenuating renal equivalent with the two drugs. The effects on the RAS
vasoconstriction at 10 weeks of age. Structurally, both were predictable. Enalapril increased PRC but reduced
drugs limited renal growth, enalapril slightly more than blood and renal Ang II levels, whereas hydralazine in-
hydralazine, although neither limited tubulointerstitial creased PRC (but not blood Ang II levels) and actually
expansion. In contrast to our studies, Keith et al did not
increased left kidney Ang II levels, when expressed per
find equivalent protection with hydralazine [22]. How-
mg renal protein.ever, in their study, adequate blood pressure control was
In general, the long-term studies support the impor-not achieved in the hydralazine group, and thus, failure
tance of blood pressure control per se but do not unequiv-to control hypertension may have contributed to the ab-
ocally support the superiority of one antihypertensivesence of renal protection. Our morphologic studies suggest
regimen over another. Previous studies of ACEI in clini-that in spite of the apparent tonic influence of the RAS,
cal ADPKD have been disappointing. In contrast to clini-effective reduction of systemic arterial pressure is bene-
cal glomerular diseases, ADPKD has not been very ame-ficial in the short term, regardless of specific effects on
nable to strategies to slow progression using ACEI [48].the RAS. However, the hemodynamic data indicate the
In the later stages, ACEI appears to accelerate renalenalapril is superior in its hemodynamic protection.
insufficiency in ADPKD [51]. It may well be that theThe long-term outcomes of rats treated with enalapril
beneficial effects of ACEI are more prominent andor hydralazine were similar in some parameters and not
promising in the early stages of cyst growth and develop-in others. Renal growth was clearly attenuated with enal-
ment, particularly with concurrent sodium restriction.april, but not hydralazine. It is interesting that long-term
As in most forms of renal disease, advanced structuralenalapril was associated with a modest, but significant
limitation of somatic growth, an effect we have noted injury in the later stages may shift the balance toward
in previous long-term ACEI studies [47]. However, the critical intrarenal dependence on Ang II, where the risks
limitation of renal hypertrophy could not be ascribed outweigh the benefits of antagonizing the RAS.
solely to this effect because the kidney/body weight ratio Taken together, these data suggest that ACEI may
was also reduced. Assuming that renal size is largely have a superior advantage in modifying some outcomes
related to renal cyst burden, then it seems likely that and risk factors (proteinuria, renal size), but may not
ACEI limited cyst number and/or size, whereas equiva- confer easily detectable benefit in others (preservation
lent antihypertensive control with hydralazine did not. of GFR and limiting development of interstitial fibrosis).
Enalapril also afforded specific protection in terms of Unlike many glomerular diseases, the data would suggest
reducing proteinuria, which is modest but progressive in that effective antihypertensive therapy is the key and
this model, as well as in limiting heart weight to values that the reduction of blood pressure itself is at least
similar to those seen in noncystic control rats. Clinically, as important as the specific choice of antihypertensive
both renal hypertrophy [11] and proteinuria [48] are risk regimen.
factors for progression of renal insufficiency; proteinuria
appears to correlate with both hypertension [49, 50] and
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